Investors and Media

Investor Relations

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

arvn-science-labs-01
arvn-science-protac-01
arvn-science-labs-06

NASDAQ: ARVN

Price:
Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest Quarterly Earnings
Events